Clinical Trial

A Study of the Effect and Safety of Sparsentan in the Treatment of Patients With IgA Nephropathy

Study acronym: PROTECT
Active, Not Recruiting Phase 3
View on ClinicalTrials.gov →
Summary
To determine the long-term (approximately 2 years) nephroprotective potential of treatment with sparsentan as compared to an angiotensin receptor blocker in patients with immunoglobulin A nephropathy (IgAN).
Protocol Amendment History 20 amendments
This ClinicalTrials.gov record has been amended 20 times since 2018-11-30; most recent amendment 2026-03-31.
Status change: Recruiting → Active, Not Recruiting 2021-06-17
Status change: Not Yet Recruiting → Recruiting 2019-01-22
Trial Details
NCT Number NCT03762850
Lead Sponsor Travere Therapeutics, Inc.
Conditions Immunoglobulin A Nephropathy
Enrollment 406 participants
Start Date 2018-12-11
Primary Completion 2023-08-07 (estimated)
Study Completion 2026-07 (estimated)
Updated on ClinicalTrials.gov 2026-04-20